Company intelligence / Profile preview
MedPacto
Seoul, Seoul, South Koreamedpacto.com ↗
- Ownership
- Private
- Employees
- ~57
- Development stage
- Other
01
Overview
MedPacto has several programs in clinical development targeting cancer and autoimmune diseases. Lead assets include monoclonal antibodies against BSP1 and TRG1, as well as vactosertib for solid tumors. The company leverages biomarker-based approaches to develop innovative therapies.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Monoclonal antibodies (mAbs)Small molecules (e.g., vactosertib)
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
Chime Biologics – strategic partnership for global biologics development and manufacturing
Beyond the preview
Go deeper on MedPacto.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MedPacto.